Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.

Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C.

J Gastrointestin Liver Dis. 2013 Mar;22(1):45-52.

PMID:
23539390
[PubMed - indexed for MEDLINE]
Free Article
2.

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.

Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.

BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266.

PMID:
21702914
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
[PubMed - indexed for MEDLINE]
4.

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR.

Lancet Oncol. 2007 Sep;8(9):797-805.

PMID:
17693134
[PubMed - indexed for MEDLINE]
5.

Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.

Lordick F.

Recent Results Cancer Res. 2012;196:201-11. doi: 10.1007/978-3-642-31629-6_14. Review.

PMID:
23129376
[PubMed - indexed for MEDLINE]
6.

Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.

Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, Jeon DG, Koh JS, Lee SY, Lim SM.

J Nucl Med. 2013 Jul;54(7):1053-9. doi: 10.2967/jnumed.112.115964. Epub 2013 May 13.

PMID:
23670899
[PubMed - indexed for MEDLINE]
Free Article
7.

Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.

Schmidt S, Dunet V, Koehli M, Montemurro M, Meuli R, Prior JO.

Acta Radiol. 2013 Oct;54(8):837-42. doi: 10.1177/0284185113485732. Epub 2013 May 9.

PMID:
23761549
[PubMed - indexed for MEDLINE]
8.

[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.

Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.

Ann Surg. 2009 Dec;250(6):888-94.

PMID:
19953708
[PubMed - indexed for MEDLINE]
9.

Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).

Heusch P, Köhler J, Wittsack HJ, Heusner TA, Buchbender C, Poeppel TD, Nensa F, Wetter A, Gauler T, Hartung V, Lanzman RS.

Eur J Radiol. 2013 Nov;82(11):2055-60. doi: 10.1016/j.ejrad.2013.05.027. Epub 2013 Jul 5.

PMID:
23830904
[PubMed - indexed for MEDLINE]
10.

(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.

zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ.

J Nucl Med. 2011 Aug;52(8):1189-96. doi: 10.2967/jnumed.110.085803. Epub 2011 Jul 15.

PMID:
21764790
[PubMed - indexed for MEDLINE]
Free Article
11.

Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.

Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA.

Rofo. 2013 Nov;185(11):1056-62. doi: 10.1055/s-0033-1350110. Epub 2013 Jul 16.

PMID:
23860802
[PubMed - indexed for MEDLINE]
Free Article
12.

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. Review.

PMID:
15464463
[PubMed - indexed for MEDLINE]
13.

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR.

J Clin Oncol. 2006 Oct 10;24(29):4692-8. Epub 2006 Sep 11.

PMID:
16966684
[PubMed - indexed for MEDLINE]
14.

Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.

Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF.

Am J Clin Oncol. 2010 Jun;33(3):257-61. doi: 10.1097/COC.0b013e3181a76a0b.

PMID:
19806035
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.

Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, Bluemke DA, Wahl R, Stearns V.

Breast Cancer Res Treat. 2011 Jul;128(1):119-26. doi: 10.1007/s10549-011-1442-1. Epub 2011 Apr 1.

PMID:
21455671
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.

Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.

Ann Surg. 2013 Jul;258(1):66-76. doi: 10.1097/SLA.0b013e31828676c4.

PMID:
23470576
[PubMed - indexed for MEDLINE]
17.

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.

Gillies RS, Middleton MR, Han C, Marshall RE, Maynard ND, Bradley KM, Gleeson FV.

Br J Surg. 2012 Feb;99(2):239-45.

PMID:
22329010
[PubMed - indexed for MEDLINE]
18.

The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.

Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ.

Am J Clin Oncol. 2012 Aug;35(4):340-4. doi: 10.1097/COC.0b013e3182118e7d.

PMID:
21422901
[PubMed - indexed for MEDLINE]
19.

Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.

Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.

Invest Radiol. 2013 May;48(5):247-55. doi: 10.1097/RLI.0b013e31828d56a1.

PMID:
23519008
[PubMed - indexed for MEDLINE]
20.

Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U.

J Clin Oncol. 2001 Jun 15;19(12):3058-65.

PMID:
11408502
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk